“…In addition, the maximum permissible amounts of residual metals, including Pd, in medicines are strictly defined by the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Q3D guidelines. , Therefore, the development of practical methods to reduce residual Pd in APIs or the reaction mixtures used in each synthetic step is strongly desired. Palladium on carbon (Pd/C), which is used as a heterogeneous catalyst for various reactions such as hydrogenations, C–H activation reactions, , and coupling reactions, can be easily removed from the reaction mixture, resulting in reduced Pd contamination in the crude reaction solution in comparison with the homogeneous Pd-catalyzed reaction . However, even a small amount of residual Pd in the product can sometimes exceed the ICH Q3D standard level and become a serious problem even for heterogeneous Pd-catalyzed reactions , because of the strong coordination ability of some functional groups for Pd species, such as aromatic rings and/or π-electron-rich unsaturated bonds within the substrates and/or products.…”